Drug intelligence / Profile preview

TJ271 + pembrolizumab

Development stage: Unknown
Lead developer: I-MAB
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TJ271 + pembrolizumab is a combination therapy under investigation for the treatment of advanced solid tumors. Pembrolizumab is a humanized monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1 and PD-L2 to enhance anti-tumor immune responses. It is approved for multiple cancers and marketed as Keytruda. TJ271 is an investigational agent being evaluated in combination with pembrolizumab in phase II clinical trials in China for advanced solid tumors; its precise mechanism of action has not been publicly disclosed as of April 2025[5][7][4].

Brand names: Keytruda

Targets

PDCD1 (Programmed cell death protein 1 receptor)B7-H3

Beyond the preview

Go deeper on TJ271 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ271 + pembrolizumab.

Explore the full profile